Roger Rich has extensive experience representing companies in areas of patent law related to biotechnology and pharmaceuticals. He advises clients in the strategic development, management, and prosecution of patent portfolios involving technologies such as small molecule pharmaceuticals, genetic analyses, molecular diagnostics, biologics, nutraceuticals, and transgenic animals, among others. Representative clients have included Abbott Laboratories, Acadia Pharmaceuticals, Amgen, AstraZeneca, Becton Dickinson, BioMarin Pharmaceutical, as well as other start-up companies, established companies, academic institutions, and investment firms.

In addition to patent procurement and portfolio management, he advises clients regarding patentability, validity, infringement, and freedom-to-operate issues and performs due diligence evaluations of patent portfolios for possible investment, licensing, or acquisition.

Prior to joining Jones Day, Roger was an associate at Pennie & Edmonds LLP.